Cochrane Review Group
Gynaecological, Neuro-oncology and Orphan Cancer
129 systematic reviews in Gynaecological, Neuro-oncology and Orphan Cancer ask 1,590 questions. 17.7% have no studies to answer them, 25.8% rest on very low certainty evidence and 25.5% reach moderate or high certainty.
Reviews
129
Questions
1,590
current versions
No studies
17.7%
Moderate or high
25.5%
No studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings 2: PLD alone vs other conventional chemotherapy Quality of life · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 2: PLD alone vs other conventional chemotherapy Overall severe adverse events (grade > 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 2 studies · 964 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Anaemia (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 5 studies · 1968 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 6 studies · 2184 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 3 studies · 1222 participants | Very low |
Summary of findings 3: PLD with chemotherapy vs PLD alone Quality of life · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 4.01 [1, 16.01] | 2 studies · 1028 participants | Very low |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 0.38 [0.2, 0.74] | 4 studies · 1900 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Progression‐free survival (PFS) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.94 [0.85, 1.04] | 4 studies · 1803 participants | Very low |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Reviews 129
Non‐pharmacological interventions for cognitive impairment due to systemic cancer treatment
CochraneSoF table
4 questions
Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer
CochraneSoF table
9 questions
Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia
CochraneSoF table
19 questions
Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer
CochraneSoF table
5 questions
Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction
CochraneSoF table
7 questions
Dance/movement therapy for improving psychological and physical outcomes in cancer patients
CochraneSoF table
6 questions
Medical interventions for high‐grade vulval intraepithelial neoplasia
CochraneSoF table
6 questions
Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia
CochraneSoF table
8 questions
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
CochraneSoF table
19 questions
Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia
CochraneSoF table
7 questions
Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
CochraneSoF table
4 questions
High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer
CochraneSoF table
11 questions
Surgical interventions for high‐grade vulval intraepithelial neoplasia
CochraneSoF table
1 questions
Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases
CochraneSoF table
6 questions
Image guided surgery for the resection of brain tumours
CochraneSoF table
1 questions
Adjuvant chemotherapy for advanced endometrial cancer
CochraneSoF table
5 questions
Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia
CochraneSoF table
4 questions
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients
CochraneSoF table
5 questions
Maintenance chemotherapy for ovarian cancer
CochraneSoF table
20 questions
Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer
CochraneSoF table
10 questions
Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy
CochraneSoF table
2 questions
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer
CochraneSoF table
6 questions
Adjuvant radiotherapy for stage I endometrial cancer
CochraneSoF table
5 questions
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy
CochraneSoF table
6 questions
Exercise interventions on health‐related quality of life for cancer survivors
CochraneSoF table
11 questions